那是摄护腺癌的指标。
合并资料目前显示摄护腺癌死亡率与整体死亡率没有显著降低。
Pooled data currently demonstrates no significant reduction in prostate cancer-specific and overall mortality.
次群组分析指出，摄护腺癌死亡率不受筛检受试者的年龄影响。
Subgroup analyses indicated that prostate cancer-specific mortality was not affected by the age at which participants were screened.
根据新研究，男性手指的长度，可提供他罹患摄护腺癌风险的线索。
The length of a man's fingers can provide clues to his risk of prostate cancer, according to new research.
针对筛检而发现的局限性摄护腺癌男性，目前正在进行的临床试验应该有助于告知治疗的决定。
The results of ongoing trials should help to inform treatment decisions for men with screen-detected localised prostate cancer.
一项刊登在《英国癌症期刊》的研究发现，食指比无名指长的男性，罹患摄护腺癌的风险明显较低。
British Journal of Cancer study found men whose index finger was longer than their ring finger were significantly less likely to develop the disease.
对于临床局限性的摄护腺癌有关治疗选择的效果的证据仍然十分欠缺，而这会持续影响临床的决策。
The lack of evidence regarding the effectiveness of treatment options for clinically localised prostate cancer continues to impact on clinical decision-making.
判断摄护腺癌筛检是否能降低摄护腺癌死亡率或总死亡率，并评估它对于生活品质及不良事件的影响。
To determine whether screening for prostate cancer reduces prostate cancer-specific mortality or all-cause mortality and to assess its impact on quality of life and adverse events.
针对局限性摄护腺癌患者关于RP与WW的利弊，目前已有的临床试验无法提供足够的证据而能有可信的声明。
The existing trials provide insufficient evidence to allow confident statements to be made about the relative beneficial and harmful effects of RP and WW for patients with localised prostate cancer.
只有一个研究(ERSPC)记录了在预先指定、55至69岁男性的次群组中，摄护腺癌死亡率有21%的显著降低。
Only one study (ERSPC) reported a 21% significant reduction of prostate cancer-specific mortality in a pre-specified subgroup of men aged 55 to 69 years.
在31个月的追踪期间，这些美国研究人员记录到117件事件，包括疾病复发、骨头肿瘤与特别因摄护腺癌导致的死亡。
During the 31 months of follow up, the us researchers recorded 117 events, including disease recurrence, bone tumours and deaths specifically caused by prostate cancer.
而氨基葡萄糖可能会借由抑制MAPK路径的磷酸化来减缓介白素- 8的表现，进而来降低摄护腺癌细胞之增生及转移。
Glucosamine appears to inhibit IL-1b-mediated MAP kinase phosphorylation to reduce IL-8 expression, and therefore to retard prostate cancer cell proliferation and migration.
2006年，我们的考科蓝文献找不出充分的证据支持或反驳使用常规大规模、选择性或伺机性的方式来进行摄护腺癌筛检。
In 2006, our Cochrane review identified insufficient evidence to either support or refute the use of routine mass, selective, or opportunistic screening for prostate cancer.
综合以上结果，我们认为，HAI-2在人类摄护腺癌细胞的侵袭转移以及间质蛋白酶的活化上扮演抑制的角色，但可提升细胞迁移能力。
The results taken together indicated that HAI-2 plays an inhibitory role in cancer cell invasion and matriptase activation while HAI-2 can promote cell migration of human prostate cancer cells.
综合以上结果，我们认为，HAI-2在人类摄护腺癌细胞的侵袭转移以及间质蛋白酶的活化上扮演抑制的角色，但可提升细胞迁移能力。
The results taken together indicated that HAI-2 plays an inhibitory role in cancer cell invasion and matriptase activation while HAI-2 can promote cell migration of human prostate cancer cells.
应用推荐